| he Changes of Serum Osteoprotegerin and Their Relationship with Bone Mineral
Density after Hormone Therapy in Postmenopausal Women
|
| 폐경 후 여성에서 호르몬 요법 후 혈청
Osteoprotegerin 농도의 변화
|
| 윤홍선,강자영,최현아,문인걸1,임창훈,정호연,한기옥,박원근,윤현구,한인권 |
| 성균관대학교 의과대학 삼성제일병원 내과 삼성제일병원 내분비 연구실1 |
|
|
| Abstract |
Background
Estrogen replacement reduces the increased rate of bone remodeling after menopause. Osteoprotegerin (OPG) is a negative regulator of osteoclast-mediated bone resorption. The studies in vitro have shown that estrogen stimulates OPG production. However, the role of OPG on physiologic bone remodeling and its regulation by estrogen in vivo remains controversial. In this study, we analyzed the association between changes in serum OPG levels and bone turnover status before and after hormone therapy (HT) in healthy postmenopausal women.
Subjects and Methods: Ninety-nine healthy postmenopausal women of Korean ethnicity, aged 42~64 yrs (52.3±4.9 yrs, mean±SD) were enrolled in our study. Serum OPG levels were assessed by a highly sensitive sandwich-type enzyme immunoassay. Serum concentrations of osteocalcin (OC) and carboxyterminal telopeptides (CTx) were determined by electrochemiluminescence immunoassays. Bone mineral density (BMD) at the lumbar spine and femoral neck was measured by dual energy x-ray absorptiometry.
Results
Baseline levels of OPG neither correlated with a bone formation marker, serum OC, nor with a bone resorption marker, serum CTx. No significant association of baseline OPG was found with baseline BMD measured at the lumbar spine and femoral neck. Serum OPG levels measured after 3 months and 1 yr of HT decreased significantly compared to baseline (p<0.001 in both). The changes in circulating OPG at 3 months of HT correlated with the changes in both serum OC (r=0.226, p=0.029) and serum CTx (r=0.214, p=0.038) at 3 months after HT. However, there was no significant association between the changes in circulating OPG at 3 months of HT and BMD values of the lumbar spine or femoral neck at 1 yr of HT.
Conclusions
Our results suggest that baseline OPG levels do not reflect the bone turnover status and that the serial measurements of serum OPG after HT are not a useful predictor for the long-term effects of estrogen on bone density. The decrea |
| Key Words:
Osteoprotegerin, Hormone therapy, Response, Bone marker, Bone mineral density |
|
PDF Links
Full text via DOI
Download Citation
